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INTRODUCTION
Myotonia congenita (MC) is a form of nondystrophic myo-
tonia characterized by impaired relaxation of skeletal muscle
after forceful voluntary contraction or following mechanical
or electrical stimulation. MC can be inherited either in an
autosomal dominant (Thomsen’s disease, OMIM 160800)
or an autosomal recessive manner (Becker’s disease, OMIM
255700). Regardless of its inheritance pattern, most cases of
MC are caused by mutations of CLCN1 encoding the human
skeletal muscle chloride channel (CLC-1), which is impor-
tant for the normal repolarization of muscle action potentials
(1, 2). The functional defects caused by CLCN1 mutations
impair CLC-1 functions and render the plasma membrane
abnormally excitable, leading to clinical myotonia and myo-
tonic discharges on the electromyography (2, 3).
CLCN1 is located on chromosome 7q35 and encompasses
35 kb in genomic DNA with 23 exons (4, 5). To date, more
than 120 disease-causing mutations in CLCN1 have been
reported, and none appears to have a particularly elevated
frequency. They are almost evenly scattered through the gene
and include small insertion/deletions, missense, nonsense,
and splicing mutations (6). Some of these mutations have
been characterized functionally. Many of these mutations
are recessive and a compound heterozygous state is presumed
in the majority of them, although it has been demonstrated
in only a few cases (7). 
In this study, we analyzed the DNA of 10 Korean MC
patients by sequencing of whole exons of CLCN1 to identi-
fy their mutations. We also evaluated clinical features of these
patients to understand the genotype-phenotype correlation
of CLCN1 mutations.
MATERIALS AND METHODS
Patients
Ten unrelated Korean patients with MC harboring CLCN1
mutations were included in this study. All of them present-
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Novel CLCN1 Mutations and Clinical Features of Korean Patients with
Myotonia Congenita
Myotonia congenita (MC) is a form of nondystrophic myotonia caused by a muta-
tion of CLCN1, which encodes human skeletal muscle chloride channel (CLC-1).
We performed sequence analysis of all coding regions of CLCN1 in patients clini-
cally diagnosed with MC, and identified 10 unrelated Korean patients harboring mu-
tations. Detailed clinical analysis was performed in these patients to identify their
clinical characteristics in relation to their genotypes. The CLCN1 mutational analyses
revealed nine different point mutations. Of these, six (p.M128I, p.S189C, p.M373L,
p.P480S, p.G523D, and p.M609K) were novel and could be unique among Kore-
ans. While some features including predominant lower extremity involvement and
normal to slightly elevated creatine kinase levels were consistently observed, gen-
eral clinical features were highly variable in terms of age of onset, clinical severity,
aggravating factors, and response to treatment. Our study is the first systematic
study of MC in Korea, and shows its expanding clinical and genetic spectrums.
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ed with sudden muscle stiffness accompanied by warm up
with use, and showed electromyographic evidence of abnor-
mal excitability of muscle fibers. Two hundred healthy Koreans
were also studied as controls. The study was reviewed and
approved by Pusan National University Hospital Institution-
al Review Board and all patients and controls provided writ-
ten informed consent for DNA acquisition and analysis. 
Mutational analysis of CLCN1
To identify the mutations in CLCN1, direct sequence anal-
ysis of whole coding regions of CLCN1 was performed. In
some patients whose biopsied skeletal muscles were avail-
able for the study, reverse transcription-polymerase chain
reaction (RT-PCR)-based sequence analysis was undertaken.
For RT-PCR, total RNA was isolated from frozen muscle
tissue of some patients and reverse transcribed to produce 1 μ g
of total DNA. The first strand cDNA was then PCR ampli-
fied by with the six overlapping cDNA primer pairs that
were presently designed. In other patients, DNA was extract-
ed from anticoagulated whole blood and sequence specific
primer pairs covering the entire coding region of CLCN1
were used as described elsewhere (4) with minor modifica-
tion. PCR amplified products were separated on 2% agarose
gels, purified, cycle-sequenced with PCR primers using the
BigDye
TM Terminator Sequencing Kit (Applied Biosystems,
Foster, CA, U.S.A.), and electrophoresed using an ABI PRI-
SM
� 3730XL DNA analyzer (Applied Biosystems). To con-
firm mutations identified in sequence analysis and to differ-
entiate them from benign polymorphisms, PCR and restric-
tion length polymorphism analysis (PCR-RFLP) was per-
formed using DNA from patients and 200 normal controls.
Restriction enzymes used in the PCR-RFLP analysis are list-
ed in Table 1. 
Clinical evaluation
Detailed clinical histories were acquired and standard neu-
rological examinations were performed for all patients with
CLCN1 mutations. Historical clinical parameters included
age of onset, distribution of muscle stiffness, presence of mus-
cle weakness, provoking factors, and family history. Physical
examinations especially focused on the presence of muscle
atrophy or hypertrophy, distribution of muscle weakness,
status of deep tendon reflexes, and types of maneuvers pro-
voking myotonia. Needle electromyography was performed
on at least two different muscles in each extremity. Routine
laboratory tests included complete blood count; liver, renal,
and thyroid function tests; blood glucose, electrolytes; serum
creatine kinase (CK) level; chest radiography; and electrocar-
diogram. A muscle biopsy was performed on five patients.
Biopsied muscles were rapidly frozen in isopentane solution
pre-chilled using liquid nitrogen, and were processed for
routine histochemical staining reactions including hema-
toxylin-eosin, modified Gomori trichrome, NADH-tetra-
zolium reductase, periodic acid-Schiff (PAS), cytochrome
oxidase (COX), and ATPase.
RESULTS
CLCN1 mutations
Nine different CLCN1 point mutations were identified;
of these, six were novel and have not been reported elsewhere
(Table 1, Figs. 1, 2). A single heterozygous mutation was iden-
tified in all patients except one (patient 3) who had two het-
erozygous mutations. All nine identified mutations were point
mutations, either missense (n=8) or nonsense (n=1). Two new
mutations were shared by two patients respectively: p.S189C
in patients 14 and 18 (Fig. 1, panel C) and p.M609K in pati-
ents 4 and 10 (Fig. 1, panel F). PCR-RFLP screening of muta-
tions listed in Table 1 did not reveal any pattern that was sim-
ilar to those in the 200 normal controls. 
Clinical features 
Clinical features are summarized in Table 2. The 10 MC
Mutations
Patients
Restriction enzymes
used for PCR-RFLP Change in cDNA Change in protein Change in codon  Location
c.384G>A p.M128I ATG>ATA Exon 3 Bcc I4
c.566C>G p.S189C TCT>TGT Exon 5 Hpy188 III 6, 9
c.929C>T p.T310M ACG>ATG Exon 8 Known mutation  2
c.949C>T p.R317X CGA>TGA Exon 8 Known mutation 8
c.1063G>A p.G355R GGG>AGG Exon 9 Known mutation 3
c.1117A>T p.M373L ATG>TTG Exon 10 Nla III 5
c.1438C>T p.P480S CCC>TCC Exon 13 Bsl I7
c.1568G>A p.G523D GGC>GAC Exon 14 BsmF I1 0
c.1826T>A p.M609K ATG>AAG Exon  16 Nla III 1, 3
Table 1. Mutations of CLCN1 identified in the study
PCR-RFLP, polymerase chain reaction and restriction length polymorphism analysis.1040 I.-S. Moon, H.-S. Kim, J.-H. Shin, et al.
patients with CLCN1 mutations included nine males and
one female, whose ages at presentation and onset were 22.5
yr (range 1-40 yr) and 9.5 yr (range 1-28 yr), respectively.
Family history was compatible with autosomal dominant
inheritance in three patients. Another two patients had affect-
ed sibling(s), which was suggestive of autosomal recessive
inheritance. In the other patients, there was no significant
family history of any neuromuscular disease.
All patients complained of intermittent myotonic stiffness
involving the limbs and trunk, which predominantly initial-
ly affected the lower extremities. The stiffness was always
provoked by sudden initiation of movement after rest (such
as grasping, walking, running, standing up, and lifting ob-
jects) and dissipated shortly after repeated use of the affect-
ed musculature. In three patients (patients 1, 8, and 9), myo-
tonic stiffness affected facial musculature in addition to limbs
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Fig. 1. Chromatograms of novel mutations identified in the study. (A) c.384G>A (p.M128I), (B) c.566C>G (p.S189C), (C) c.1117A>T (p.M373L),
(D) c.1438C>T (p.480S), (E) c.1568G>A (p.G523D), (F) c.1826T>A (p.M609K).
Fig. 2. Two-dimensional representation of the structure of a CLC subunit (9) showing the locations of mutations identified in this study.
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and trunk, either as chewing difficulty, facial stiffness, speech
disturbance, or eye opening difficulty in variable combina-
tions. Two patients considered that there was a worsening of
their symptoms by certain physiological factors including
cold exposure (patient 6, p.S189C mutant and patient 7,
p.P480S mutant) and fasting (patient 7). Myotonia could
be provoked by tapping on skeletal muscles or following a
firm hand grip in all patients. In five patients (patients 1, 3,
4, 5, and 9), myotonia was also provoked by tapping of the
tongue as the ‘napkin ring’ sign. The degree of myotonia-
induced muscle stiffness was highly variable, from mild dis-
comfort caused by intermittent leg stiffness a few times a
day (patient 4) to frequent and severe focal or generalized
muscle stiffness provoked by virtually every motion attempt-
ed (patients 1 and 9). Patient 1 also complained of an accom-
panying myalgic pain during attacks of myotonic stiffness.
Four patients complained of muscle weakness in addition
to the myotonic stiffness. Patient 1 (p.M609K mutant) ini-
tially experienced intermittent short lasting muscle weak-
ness of limbs following myotonic stiffness beginning at 8-
yr-of-age. His weakness became more frequent and longer-
lasting, and constant muscle weakness began to develop from
the age of 19. Initially, fixed weakness that arose in his hands
and feet soon began to spread to other limb muscles. At age
20, his limb muscle power as graded by the modified Medi-
cal Research Council muscle power grading system was 4 in
proximal/distal upper/lower limbs. His hand grip power as
measured by a hand dynamometer was 9 kilograms on the
right and 8 kilograms on the left. Patients 3 (p.M609K+
p.G355R), 9 (p.S189C) and 10 (p.G523D) also had short-
lasting muscle weakness following myotonic stiffness. 
Seven patients (70.0%) showed muscular hypertrophy
that varied in both degree and distribution. Among them,
patients 1 and 9 showed the most prominent generalized
form of muscular hypertrophy. A female patient (patient 7)
also showed mild muscle hypertrophy. 
Needle electromyography was performed in all patients
except for patient 5, and all showed evidence of abnormal
muscle fiber excitability, mostly in the form of myotonic
discharges, except in patients 6 and 7, who experienced show-
ers of positive sharp waves instead. Muscle biopsy was per-
formed in five patients and only two of them showed mild
myopathic patterns; patient 1 displayed a few regenerating
fibers with type 1 fiber predominance, and patient 7 dis-
played mild type 2B fiber atrophy. Several drugs including
mexiletine, phenytoin, and caramabazepine were tried and
showed various responses (Table 2). 
DISCUSSION 
The present study identified six novel CLCN1 mutations
from 10 unrelated Korean MC patients. The c.384G>A
mutation located in the transmembrane region of helix B
(Fig. 2) is expected to change the highly conserved amino
acid methionine to isoleucine (p.M128I). A myotonia-asso-
ciated mutation involving the same codon (M128V) has
been reported previously (8). Another mutation, c.566C>G
No. Gender
Age at 
presenta-
tion (yr)
Onset
age
(yr)
Inheritance
(affected 
family)
Muscle
hyper-
trophy
Transient
weak-
ness
Cold 
sensi-
tivity
CK
level
EMG
finding
Severity 
grade*
Response
to treat-
ment
�
Mutation
1 M 20 7 Sporadic + +  - 138 IU Myotonia 5 Poor p.M609K
(+ fixed)
2 M 33 16 AR + -- 92 IU Myotonia 3 Poor p.T310M
(brother)
3 M 1 1 Sporadic + ? - 138 IU Myotonia 3 Poor p.M609K 
+ p.G355R
4 M 21 14 AR --- 268 IU Myotonia 2 Poor p.M128I
(brother)
5 M 34 28 Sporadic + + - ND ND 4 ND p.M373L
6M 2 0 5 A D --+ 174 IU PSWs 3 Fair p.S189C
7F 3 2 7 A D + - + 121 IU PSWs 3 Excellent p.P480S
8 M 5 2 Sporadic + -- 99 IU Myotonia 3 Excellent p.R317X
9M 1 9 7 A D + + - 346 IU Myotonia 4 Poor p.S189C
10 M 40 8 Sporadic - + - 78 IU Myotonia 4 Excellent p.G523D
Table 2. Clinical features of the patients with CLCN1 mutation
*Severity of myotonia congenita was graded as follows; (1) no symptoms, but unequivocal myotonia at examination, (2) mild (and/or fluctuating) sym-
ptoms, (3) pronounced myotonia, but no transient weakness, (4) pronounced myotonia with transient weakness,but without dystrophic features, and
(5) pronounced myotonia, transient weakness, and dystrophic features (Colding-Jorgensen, 2005); 
� Response to treatment was judged as follows:
excellent; complete or near-complete abolition of symptom, good; >70% reduction of frequency and duration of myotonic stiffness, fair; <70% and
>30% reduction of frequency and duration of myotonic stiffness, poor; <30% reduction of frequency and duration of myotonic stiffness.
M, male; F, female; AR, autosomal recessive; AD, autosomal dominant; IU, international unit; ND, not done; PSWs, showers of positive sharp waves
with or without complex repetitive discharges.1042 I.-S. Moon, H.-S. Kim, J.-H. Shin, et al.
(S189C), present in two of the 10 patients (patients 6 and 9)
is located in the highly conserved CLC-1 protein signature
region (GSGIPE) (Fig. 2). Since this region is thought to be
a chloride ion binding site, the introduction of the much
larger sulfhydryl group of cysteine in place of the serine hy-
droxyl might be anticipated to have a significant effect on
the conductance of the CLC-1 channel (9, 10). Since both of
these patients showed an autosomal dominant inheritance
pattern of disease, c.566C>G (p.S189C) is most likely asso-
ciated with Thomsen’s disease. Previously present, p.S189C
had been evaluated as a site-directed mutant expressed in cul-
tured tsA201 cells. However, the observation of a relatively
normal chloride current fails to support a pathogenic role of
the mutation in the development of myotonia (11).
The c.1117A>T mutation, which is located in the helix J
transmembrane domain (Fig. 2), changes the codon for meth-
ionine to leucine (p.M373L). Since no pathogenic missense
mutation has previously been found in helix J, this mutant
will require functional study for the verification of its patho-
genicity. Another new mutation, c.1438C>T (p.P480S), is
located in the cytoplasmic loop connecting helices M and N
(Fig. 2), where it changes the highly conserved amino acid
proline to serine. Since three different missense mutations
involving the same codon (p.P480T, p.P480L, and p.P480H)
have been reported previously (12-14), its pathogenicity is
almost certain. A novel mutation, c.1568G>A (p.G523D),
is located in helix O (Fig. 2) at a glycine that is fairly con-
served between different species. Since no pathogenic muta-
tion has been identified in this area, its verification will also
depend on functional study. Another novel mutation, c.18-
26T>A (p.M609K), which was present in two patients, is
also notable. The mutated amino acid, methionine, is locat-
ed at the CBS1 domain (Fig. 2) and is highly conserved be-
tween different CLC proteins as well as between different
species. CBS (cystathione β -synthase) domains are sequence
motifs of approximately 60 amino acids that occur in CBS
and many other proteins in all organisms (15). Recently, the
CBS domains of CLC-1 have been suggested to function as
sensors of cellular energy status that act by binding ATP,
which is crucial for channel opening (16). Another study
also showed that the structure of CBS domains from CLC
channels is highly conserved, and mutations in CBS domains
were suggested to affect protein-protein interactions within
CLC protein subunits as well as between the two subunits
of CBS dimers, thereby influencing the voltage dependence
of gating by acting on the common gate (17). Only one mis-
sense mutation affecting the CBS1 domain (p.A659V) has
been reported so far, but has not yet been verified by a func-
tional study (13). Thus, the functional study of the present-
ly-reported novel mutation c.1826T>A (p.M609K) could
be important to elucidate the role of the CBS1 domain in
channel function. Other presently identified mutations c.929-
C>T (p.T310M), c.949C>T (p.R317X), and c.1063G>A
(p.G355R) have been previously reported (18-20).
One of the interesting findings in our study was the appar-
ent male predominance of MC in Korea. We had only one
female patient and her disease was relatively mild. Although
there is no direct evidence that males are more frequently
affected than females, it seems clear that myotonia, both cli-
nically and electrically, may be more pronounced in males,
especially in the recessive form of disease (21-23). This gen-
der difference in MC was not well-understood until recent-
ly, when the sex hormones testosterone, progesterone, and
17β -estradiol were implicated in gender differences and pre-
gnancy-related symptoms of MC (24).
Our patients showed a broad spectrum of clinical severity,
consistent with a previous study (21). Patient 1 showed the
most severe symptoms of the disease: marked muscular hy-
pertrophy, severe myotonia, and fixed weakness of the limbs
leading to significant impediment to daily life. Unfortunate-
ly, we could not determine whether the mode of inheritance
was dominant or recessive in this patient, since no other fa-
mily member was affected and only a single mutant allele
(p.M609K) was identified. 
Patient 9 (p.S189C) is also noteworthy because of the ex-
ceptionally severe clinical features for an autosomal dominant
MC: marked muscular hypertrophy, severe myotonia, and
transient weakness. This might be related to the site of the
mutation within the signature region of the channel. How-
ever, another patient with same mutation (patient 6) showed
only a moderate degree of severity without muscular hyper-
trophy or transient weakness, suggesting that the type and
location of the mutation is unlikely to be the sole determi-
nant of clinical severity. Differential allelic expression might
be responsible for this kind of phenotypic variability between
individuals sharing same mutation (25).
Two of our patients complained of worsening of myotonia
during cold exposure (patients 6, 7) and fasting (patient 7).
So far, many stimuli within normal physiological range have
been implicated as aggravating factors for myotonia, includ-
ing cold temperature, pregnancy, emotional stress, fasting,
and fatigue (8, 26). Cold sensitivity had been considered as
one of the features differentiating paramyotonia congenita
from other nondystrophic myotonias, but some clinical and
electromyographic studies have confirmed that it is also com-
mon in patients with MC (8, 14, 27, 28). It has been sug-
gested that the presence of cold sensitivity might be related
to the type of CLCN1 mutation (14, 28). Our study further
supports the growing consensus that cold sensitivity should
not be considered as a clinical feature unique to paramyoto-
nia congenita among different types of nondystrophic myoto-
nias. 
While many patients with MC can manage their lives with-
out medication, treatment can be of help when myotonic
stiffness interferes with everyday activity and is associated
with pain. We tried various drugs including mexiletine,
carbamazepine, or phenytoin in our patients, and the response
was highly variable. Of the four patients treated with mex-CLCN1 Mutations in Korean Patients with Myotonia Congenita 1043
iletine, three patients showed dramatic improvement of myo-
tonic stiffness while the improvement in one was moderate,
while in other patients no treatment was effective. Although
mexiletine is currently considered as a drug of choice in pati-
ents with MC (29, 30), it has no known direct effect on chlo-
ride channels and may simply attenuate myotonic stiffness
by blocking, and thereby reducing the availability of, some
sodium channels for action potential production (21).
In conclusion, we report six novel CLCN1 mutations in
Korean patients with MC, and suggest their clinical features
are quite variable even between patients sharing a same muta-
tion. 
ACKNOWLEDGMENT
We would like express our thanks to Professor Allan Bre-
tag from the Sansom Institute, School of Pharmacy and Me-
dical Sciences, University of South Australia, for his valuable
comments on our new CLCN1 mutations. 
REFERENCES
1. Koch MC, Steinmeyer K, Lorenz C, Ricker K, Wolf F, Otto M, Zoll
B, Lehmann-Horn F, Grzeschik KH, Jentsch TJ. The skeletal mus-
cle chloride channel in dominant and recessive human myotonia.
Science 1992; 257: 797-800.
2. George AL Jr, Crackower MA, Abdalla JA, Hudson AJ, Ebers GC.
Molecular basis of Thomsen’s disease (autosomal dominant myoto-
nia congenita). Nat Genet 1993; 3: 305-10.
3. Kubisch C, Schmidt-Rose T, Fontaine B, Bretag AH, Jentsch TJ.
ClC-1 chloride channel mutations in myotonia congenita: variable
penetrance of mutations shifting the voltage dependence. Hum Mol
Genet 1998; 7: 1753-60.
4. Lorenz C, Meyer-Kleine C, Steinmeyer K, Koch MC, Jentsch TJ.
Genomic organization of the human muscle chloride channel CIC-1
and analysis of novel mutations leading to Becker-type myotonia.
Hum Mol Genet 1994; 3: 941-6.
5. Lehmann-Horn F, Rudel R. Molecular pathophysiology of voltage-
gated ion channels. Rev Physiol Biochem Pharmacol 1996; 128:
195-268.
6. Lossin C, George AL Jr. Myotonia congenita. Adv Genet 2008; 63:
25-55.
7. Lehmann-Horn F, Mailander V, Heine R, George AL. Myotonia lev-
ior is a chloride channel disorder. Hum Mol Genet 1995; 4: 1397-402.
8. Colding-J  rgensen E, Dun  M, Schwartz M, Vissing J. Decrement
of compound muscle action potential is related to mutation type in
myotonia congenita. Muscle Nerve 2003; 27: 449-55.
9. Dutzler R, Campbell EB, Cadene M, Chait BT, MacKinnon R. X-ray
structure of a ClC chloride channel at 3.0 A reveals the molecular
basis of anion selectivity. Nature 2002; 415: 287-94.
10. Dutzler R, Campbell EB, MacKinnon R. Gating the selectivity filter
in ClC chloride channels. Science 2003; 300: 108-12.
11. Fahlke C, Desai RR, Gillani N, George AL Jr. Residues lining the
inner pore vestibule of human muscle chloride channels. J Biol Chem
2001; 276: 1759-65.
12. Pusch M. Myotonia caused by mutations in the muscle chloride chan-
nel gene CLCN1. Hum Mutat 2002; 19: 423-34.
13. Sasaki R, Ichiyasu H, Ito N, Ikeda T, Takano H, Ikeuchi T, Kuzuhara
S, Uchino M, Tsuji S, Uyama E. Novel chloride channel gene muta-
tions in two unrelated Japanese families with Becker’s autosomal reces-
sive generalized myotonia. Neuromuscul Disord 1999; 9: 587-92.
14. Fialho D, Schorge S, Pucovska U, Davies NP, Labrum R, Haworth
A, Stanley E, Sud R, Wakeling W, Davis MB, Kullmann DM, Hanna
MG. Chloride channel myotonia: exon 8 hot-spot for dominant-neg-
ative interactions. Brain 2007; 130: 3265-74.
15. Bateman A. The structure of a domain common to archaebacteria
and the homocystinuria disease protein. Trends Biochem Sci 1997;
22: 12-3.
16. Scott JW, Hawley SA, Green KA, Anis M, Stewart G, Scullion GA,
et al. CBS domains form energy-sensing modules whose binding of
adenosine ligands is disrupted by disease mutations. J Clin Invest
2004; 113: 274-84.
17. Este@vez R, Pusch M, Ferrer-Costa C, Orozco M, Jentsch TJ. Func-
tional and structural conservation of CBS domains from CLC chlo-
ride channels. J Physiol 2004; 557: 363-78.
18. Deymeer F, Cakirkaya S, Serdarog(lu P, Schleithoff L, Lehmann-
Horn F, Ru_del R, Ozdemir C. Transient weakness and compound
muscle action potential decrement in myotonia congenita. Muscle
Nerve 1998; 21: 1334-7.
19. Meyer-Kleine C, Steinmeyer K, Ricker K, Jentsch TJ, Koch MC.
Spectrum of mutations in the major human skeletal muscle chloride
channel gene (CLCN1) leading to myotonia. Am J Hum Genet 1995;
57: 1325-34.
20. Wu FF, Ryan A, Devaney J, Warnstedt M, Korade-Mirnics Z, Poser
B, Escriva MJ, Pegoraro E, Yee AS, Felice KJ, Giuliani MJ, Mayer
RF, Mongini T, Palmucci L, Marino M, Ru_del R, Hoffman EP, Fahl-
ke C. Novel CLCN1 mutations with unique clinical and electrophys-
iological consequences. Brain 2002; 125: 2392-407.
21. Colding-J  rgensen E. Phenotypic variability in myotonia congenita.
Muscle Nerve 2005; 32: 19-34.
22. Maila_nder V, Heine R, Deymeer F, Lehmann-Horn F. Novel muscle
chloride channel mutations and their effects on heterozygous carri-
ers. Am J Hum Genet 1996; 58: 317-24.
23. Deymeer F, Lehmann-Horn F, Serdarog(lu P, Cakirkaya S, Benz S,
Ru_del R, Ozdemir C. Electrical myotonia in heterozygous carriers
of recessive myotonia congenita. Muscle Nerve 1999; 22: 123-5.
24. Fialho D, Kullmann DM, Hanna MG, Schorge S. Non-genomic effects
of sex hormones on CLC-1 may contribute to gender differences in
myotonia congenita. Neuromuscul Disord 2008; 18: 869-72.
25. Dun   M, Colding-J rgensen E, Grunnet M, Jespersen T, Vissing J,
Schwartz M. Difference in allelic expression of the CLCN1 gene and
the possible influence on the myotonia congenita phenotype. Eur J
Hum Genet 2004; 12: 738-43.
26. Hakim CA, Thomlinson J. Myotonia congenita in pregnancy. J Obstet
Gynaecol Br Commonw 1969; 76: 561-2.
27. Michel P, Sternberg D, Jeannet PY, Dunand M, Thonney F, Kress
C
°1044 I.-S. Moon, H.-S. Kim, J.-H. Shin, et al.
W, Fontaine B, Fournier E, Kuntzer T. Comparative efficacy of repet-
itive nerve stimulation, exercise, and cold in differentiating myoton-
ic disorders. Muscle Nerve 2007; 36: 643-50.
28. Fournier E, Viala K, Gervais H, Sternberg D, Arzel-He@zode M, La-
fore^t P, Eymard B, Tabti N, Willer JC, Vial C, Fontaine B. Cold ex-
tends electromyography distinction between ion channel mutations
causing myotonia. Ann Neurol 2006; 60: 356-65.
29. Ru_del R, Dengler R, Ricker A, Haass A, Emser W. Improved thera-
py of myotonia with the lidocaine derivative tocainide. J Neurol 1980;
222: 275-8.
30. Meola G, Sansone V. Therapy in myotonic disorders and in muscle
channelopathies. Neurol Sci 2000; 21 (5 Suppl): S953-61.